Rankings/Tempus AI
Tempus AI logo

Tempus AI

NativeApplied AIPublic · TEMUpdated November 15, 2026

The company sitting on the most valuable clinical dataset in AI — and building a real business on top of it.

Website
tempus.com
Founded
2015
CEO
Eric Lefkofsky
HQ
Chicago, IL, United States
Stage
Public
Revenue
$1B–$10B
Employees
1001-5000
Flag a data issue
57.2Bluescore
Momentum71.5
Market MapCategory Leaders
Rank change (7d)▲ 2

Executive Summary

Updated Nov 15, 2026

What they do

  • Runs genomic testing for cancer, including xT CDx and MRD tests, at national scale
  • Licenses de-identified multimodal clinical and molecular data to pharma for research
  • Builds FDA-cleared ECG-AI devices, pathology AI and AI tools that support doctors' decisions

Why it matters

  • Q3 2026 revenue reached a record $411.5M; 2026 guidance is about $1.6B
  • Pharma backing includes AstraZeneca, Bristol-Myers Squibb and Recursion data and model agreements
  • Paige and the pending Personalis deal deepen its pathology AI and MRD offerings

Best fit

  • Pharma and biotech teams that need real-world oncology data for R&D
  • Health systems and oncology practices that want genomic testing linked to decision support
  • Cardiology programs adopting FDA-cleared ECG-AI screening for undiagnosed heart disease

Watch-outs

  • 2026 class actions over alleged unlawful disclosure of patients' genetic data
  • Still loss-making on GAAP, with adjusted EBITDA guidance of only about $65M for 2026
  • Integrating the $1.5B Personalis all-stock deal may distract execution and dilute shareholders

Products & Offerings

Tempus Genomics (xT CDx, xF, xR, MRD)

Tumor and liquid-biopsy genomic profiling and molecular residual disease tests for precision oncology, including the FDA-approved xT CDx.

PlatformEnterpriseFlagship

Tempus Data & Services (Insights / Lens)

Licensing of de-identified multimodal real-world clinical and molecular data, plus analytics tools for pharma and biotech R&D.

DataEnterpriseHigh Growth

Tempus One

Generative AI clinical assistant that gives physicians fast access to patient test results, records and treatment insights.

EnterpriseEnterpriseLive

Tempus ECG-AI

FDA-cleared AI software that detects atrial fibrillation risk, low ejection fraction, pulmonary hypertension and mitral regurgitation from standard ECGs.

EnterpriseEnterpriseEmerging

Paige Digital Pathology

AI pathology products and an oncology foundation model, acquired with Paige in 2025 for $81.25M.

ModelEnterpriseLive

Latest News

Analyst VerdictShortlist

Updated Nov 15, 2026

Tempus is one of the largest and most proven AI-driven precision oncology vendors, with fast revenue growth, multiple FDA-cleared products and major pharma data partnerships. Pharma R&D teams and health systems buying oncology genomics or real-world data should include it, alongside Foundation Medicine, Guardant, Caris and Flatiron. Before committing, check its data-governance and consent practices given the 2026 genetic-data litigation, and get contract protections in case the Personalis integration disrupts service.

Signal Provenance

Latest observation date and source for each signal category

Signal CategoryLast UpdatedSource
Funding Signals
Last funding round, Funding stage
Nov 12, 2026Cited web research
Hiring Velocity
Headcount, Headcount growth
Nov 15, 2026Research agents (estimate)
Technical Output
Research papers, GitHub activity
Nov 11, 2026Hugging Face Hub + news feed + research agents
News Sentiment
News mentions, News sentiment
Nov 15, 2026Verified news feed
Partnership Signals
Enterprise partnerships, Distribution partners
Nov 12, 2026Research agents (estimate)
Revenue Indicators
ARR estimate, Revenue growth
Nov 15, 2026SEC filings
Leadership Signals
CEO tenure, Founder-led
Nov 15, 2026Research agents (estimate)
Competitive Position
Category rank, Market share
Nov 15, 2026Research agents (estimate)

Why this Bluescore?

6 dimensions, each scored 0–10 against all 250 companies. Each adds its weight × score to the Bluescore — see methodology

Tempus AI's Bluescore of 57.2 rests most on Investment Momentum (9.0, top 3%) and Data & Model Moat (6.8, top 11%). Its weakest area is Product Depth (4.2, 38th percentile).

In plain English

Tempus AI's Bluescore of 57.2 places it at #58 of 247, with its strongest contributions coming from Investment Momentum at 9.0 of 10 (97th percentile), Data & Model Moat at 6.8 of 10 (89th percentile), and Business Model & Revenue at 6.3 of 10 (82nd percentile). The biggest drag is Product Depth, which scores 4.2 of 10 (38th percentile) on a 21% weight and still has 12.1 points left, the largest gap of any dimension. Improving Product Depth would move the Bluescore more than any other change, because it carries a large weight and is currently one of the weakest scores.

Written by AI from the scores below and checked against them; updated nightly.

D1 · Business Model & Revenue (21%)
6.3
+13.2 of 21 pts · Top 18%
D2 · Product Depth (21%)
4.2
+8.9 of 21 pts · 38th pct
D3 · Data & Model Moat (19%)
6.8
+12.9 of 19 pts · Top 11%
D4 · Talent & Research (16%)
4.0
+6.4 of 16 pts · 53rd pct
D5 · Customer Adoption (13%)
5.2
+6.8 of 13 pts · 50th pct
D6 · Investment Momentum (10%)
9.0
+9.0 of 10 pts · Top 3%

Traction Signals

Last Round

Public

Risks

Updated Nov 15, 2026

Class actions filed April 2026 allege unlawful disclosure of genetic data for AI training
High
GAAP operating losses continue despite revenue growth; profitability depends on cost discipline
Medium
$1.5B all-stock Personalis acquisition carries integration, dilution and execution risk
Medium
Test revenue depends on payer reimbursement and FDA/LDT regulatory changes
Medium
A 2025 short-seller report questioned its AI claims and accounting; the related lawsuit was dropped
Low
Feedback